AB Science Granted US Patent for Masitinib in Sickle Cell Disease, Protection Until 2040

Reuters00:58
AB Science Granted US Patent for Masitinib in Sickle Cell Disease, Protection Until 2040

AB Science SA has announced that the United States Patent Office has formally granted a patent for the use of masitinib in the treatment of sickle cell disease, with protection extending until November 2040. The patent covers methods of treating sickle cell disease based on preclinical data. This move strengthens the intellectual property position of masitinib for an additional indication with high unmet medical need. The company’s phase 2 clinical development of masitinib in sickle cell disease, which aims to demonstrate efficacy in treating acute and chronic complications, is fully funded.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. AB Science SA published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW1001156330-en) on December 22, 2025, and is solely responsible for the information contained therein.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment